Jeff Yass’s Lexeo Therapeutics LXEO Stock Holding History

Jeff Yass’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$57.4K	–	14066
2026 Q1	$57.4K	Sell	10,000 -2,100	-17%	-$14.9K	﹤0.01%	12599
2025 Q4	$120K	Sell	12,100 -800	-6%	-$7.3K	﹤0.01%	11350
2025 Q3	$85.7K	Buy	+12,900	New	+$62.4K	﹤0.01%	11652
2025 Q2	–	Sell	-12,300	Closed	-$42.7K	–	13279
2025 Q1	$42.7K	Buy	+12,300	New	+$54.5K	﹤0.01%	11911

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jeff Yass's LXEO Position: Q2 2026 in Review

Jeff Yass sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 46,998 shares — an estimated $254K sold.

Jeff Yass first reported a position in LXEO in Q1 2024 and held it in 7 quarters. The position peaked at $367K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Jeff Yass reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 46,998 Lexeo Therapeutics shares in Q2 2026, an estimated $254K.
Jeff Yass first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 7 quarters.
Jeff Yass's Lexeo Therapeutics position peaked at $367K in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.